BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 7138909)

  • 21. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
    Becker E; Richardson DR
    J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor or heme synthesis.
    Ponka P; Wilczynska A; Schulman HM
    Biochim Biophys Acta; 1982 Feb; 720(1):96-105. PubMed ID: 7059619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.
    Chen YL; Kong X; Xie Y; Hider RC
    J Inorg Biochem; 2018 Mar; 180():194-203. PubMed ID: 29329026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate.
    Hermes-Lima M; Ponka P; Schulman HM
    Biochim Biophys Acta; 2000 Oct; 1523(2-3):154-60. PubMed ID: 11042379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Membrane transport of non-transferrin-bound iron by reticulocytes.
    Morgan EH
    Biochim Biophys Acta; 1988 Sep; 943(3):428-39. PubMed ID: 3415985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs.
    Buss JL; Neuzil J; Ponka P
    Arch Biochem Biophys; 2004 Jan; 421(1):1-9. PubMed ID: 14678779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyridoxal isonicotinoyl hydrazone inhibits iron-induced ascorbate oxidation and ascorbyl radical formation.
    Maurício AQ; Lopes GK; Gomes CS; Oliveira RG; Alonso A; Hermes-Lima M
    Biochim Biophys Acta; 2003 Mar; 1620(1-3):15-24. PubMed ID: 12595068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
    Bláha K; Cikrt M; Nerudová J; Ponka HF
    Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria.
    Zhang AS; Sheftel AD; Ponka P
    Blood; 2005 Jan; 105(1):368-75. PubMed ID: 15331447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents.
    Ponka P; Borová J; Neuwirt J; Fuchs O; Necas E
    Biochim Biophys Acta; 1979 Aug; 586(2):278-97. PubMed ID: 476142
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate.
    Chitambar CR; Boon P; Wereley JP
    Clin Cancer Res; 1996 Jun; 2(6):1009-15. PubMed ID: 9816262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis.
    Brewer CT; Yang L; Edwards A; Lu Y; Low J; Wu J; Lee RE; Chen T
    Toxicol Sci; 2019 Mar; 168(1):209-224. PubMed ID: 30517741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
    Buss JL; Arduini E; Shephard KC; Ponka P
    Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosynthesis of heme in immature erythroid cells. The regulatory step for heme formation in the human erythron.
    Gardner LC; Cox TM
    J Biol Chem; 1988 May; 263(14):6676-82. PubMed ID: 3360800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks.
    Hermes-Lima M; Nagy E; Ponka P; Schulman HM
    Free Radic Biol Med; 1998 Nov; 25(8):875-80. PubMed ID: 9840731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent.
    Ponka P; Borová J; Neuwirt J; Fuchs O
    FEBS Lett; 1979 Jan; 97(2):317-21. PubMed ID: 761636
    [No Abstract]   [Full Text] [Related]  

  • 37. Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation.
    Hermes-Lima M; Gonçalves MS; Andrade RG
    Mol Cell Biochem; 2001 Dec; 228(1-2):73-82. PubMed ID: 11855743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities.
    Richardson DR
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2061-3. PubMed ID: 9303419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preferential utilization in vitro of iron bound to diferric transferrin by rabbit reticulocytes.
    Zapolski EJ; Princiotto JV
    Biochem J; 1977 Aug; 166(2):175-9. PubMed ID: 911316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on *OH formation by the Fenton reaction.
    Hermes-Lima M; Santos NC; Yan J; Andrews M; Schulman HM; Ponka P
    Biochim Biophys Acta; 1999 Feb; 1426(3):475-82. PubMed ID: 10076064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.